Investigating drug repositioning opportunities in FDA drug labels through topic modeling
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Background: Drug repositioning offers an opportunity to revitalize the slowing drug discovery pipeline by finding new uses for currently existing drugs. Our hypothesis is that drugs sharing similar side effect profiles are likely to be effective for the same disease, and thus repositioning opportunities can be identified by finding drug pairs with similar side effects documented in U.S. Food and Drug Administration (FDA) approved drug labels. The safety information in the drug labels is usually obtained in the clinical trial and augmented with the observations in the post-market use of the drug. Therefore, our drug repositioning approach can take the advantage of more comprehensive safety information comparing with conventional de novo approach. Method: A probabilistic topic model was constructed based on the terms in the Medical Dictionary for Regulatory Activities (MedDRA) that appeared in the Boxed Warning, Warnings and Precautions, and Adverse Reactions sections of the labels of 870 drugs. Fifty-two unique topics, each containing a set of terms, were identified by using topic modeling. The resulting probabilistic topic associations were used to measure the distance (similarity) between drugs. The success of the proposed model was evaluated by comparing a drug and its nearest neighbor (i.e., a drug pair) for common indications found in the Indications and Usage Section of the drug labels. Results: Given a drug with more than three indications, the model yielded a 75% recall, meaning 75% of drug pairs shared one or more common indications. This is significantly higher than the 22% recall rate achieved by random selection. Additionally, the recall rate grows rapidly as the number of drug indications increases and reaches 84% for drugs with 11 indications. The analysis also demonstrated that 65 drugs with a Boxed Warning, which indicates significant risk of serious and possibly life-threatening adverse effects, might be replaced with safer alternatives that do not have a Boxed Warning. In addition, we identified two therapeutic groups of drugs (Musculo-skeletal system and Anti-infective for systemic use) where over 80% of the drugs have a potential replacement with high significance. Conclusion: Topic modeling can be a powerful tool for the identification of repositioning opportunities by examining the adverse event terms in FDA approved drug labels. The proposed framework not only suggests drugs that can be repurposed, but also provides insight into the safety of repositioned drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drug repositioning: identifying and developing new uses for existing drugs
Ashburn, T. T., & Thor, K. B. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1468 · Cited by 3,237
Drug target identification using side-effect similarity
Campillos, M., Kuhn, M., Gavin, A.-C., Jensen, L. J., & Bork, P. (2008) · Science · doi:10.1126/science.1158140 · Cited by 1,248 · cited 2×
“[14] investigated off-target effects by integrating side effect profiles with chemical structures and identified several new drugtarget interactions.”
BackgroundTHALIDOMIDE AND CONGENITAL ABNORMALITIES
Mcbride, W. G. (1961) · The Lancet · doi:10.1016/s0140-6736(61)90927-8 · Cited by 1,141
A side effect resource to capture phenotypic effects of drugs
Kuhn, M., Campillos, M., Letunic, I., Jensen, L. J., & Bork, P. (2010) · Molecular Systems Biology · doi:10.1038/msb.2009.98 · Cited by 899
FDA-approved drug labeling for the study of drug-induced liver injury
Chen, M., Vijay, V., Shi, Q., Liu, Z., Fang, H., & Tong, W. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.05.007 · Cited by 406
Self-citationDrug repositioning for orphan diseases
Sardana, D., Zhu, C., Zhang, M., Gudivada, R. C., Yang, L., & Jegga, A. G. (2011) · Briefings in Bioinformatics · doi:10.1093/bib/bbr021 · Cited by 228
Cited by
Jin, G., & Wong, S. T. C. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2013.11.005 · Cited by 416
An overview of topic modeling and its current applications in bioinformatics
Liu, L., Tang, L., Dong, W., Yao, S., & Zhou, W. (2016) · SpringerPlus · doi:10.1186/s40064-016-3252-8 · Cited by 392
Redundancy-Aware Topic Modeling for Patient Record Notes
Cohen, R., Aviram, I., Elhadad, M., & Elhadad, N. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087555 · Cited by 71
“In the biomedical domain, probabilistic graphical models like LDA are an emerging technology only recently applied to EHR data [13–17], biomedical corpora [18–20], and consumer health resources [21].”
MethodFang, H., Harris, S. C., Liu, Z., Zhou, G., Zhang, G., Xu, J., Rosario, L., Howard, P. C., & Tong, W. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.06.006 · Cited by 56
Self-citationPriotti, J., Baglioni, M. V., García, A., Rico, M. J., Leonardi, D., Lamas, M. C., & Menacho Márquez, M. (2018) · AAPS PharmSciTech · doi:10.1208/s12249-018-1169-y · Cited by 27
Metadata
- Authors
- Bisgin, H., Liu, Z., Kelly, R., Fang, H., Xu, X., & Tong, W.
- Venue
- BMC Bioinformatics
- Published
- 2012-09
- Volume
- 13
- Issue
- S15
- Pages
- S6-S6
- ISSN
- 1471-2105 (ISSN-L)
- OpenAlex
- W2129974743
- Cited by
- 76
- References
- 6
- FWCI
- 6.45
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Investigating drug repositioning opportunities in FDA drug labels through topic modeling. https://app.cochat.ai/papers/10.1186/1471-2105-13-s15-s6
- The paper
- Bisgin, H., Liu, Z., Kelly, R., Fang, H., Xu, X., & Tong, W. (2012). Investigating drug repositioning opportunities in FDA drug labels through topic modeling. BMC Bioinformatics. https://doi.org/10.1186/1471-2105-13-s15-s6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.